Literature DB >> 14659653

Investigation of methicillin-resistant Staphylococcus aureus showing reduced vancomycin susceptibility isolated from a patient with infective endocarditis.

Yoko Takayama1, Hideaki Hanaki, Kazuhiko Irinoda, Hideya Kokubun, Kazunari Yoshida, Keisuke Sunakawa.   

Abstract

A patient with infective endocarditis (IE) caused by methicillin-resistant Staphylococcus aureus (MRSA) was treated with vancomycin (VAN). VAN was ineffective, although therapeutic drug monitoring (TDM) indicated that the recommended trough level was maintained. Five MRSA isolates obtained at various times were analyzed to determine the minimum inhibitory concentration (MIC) and were subjected to population analysis, simulation analysis pulsed-field gel electrophoresis (PFGE). MRSA susceptible to VAN was isolated before and during the early stage of treatment, while an MRSA strain showing reduced VAN MIC was isolated during treatment. Simulation analysis indicated that the viable bacterial count only decreased to 10(-3) to 10(-4) cells after 72 h of incubation. The five MRSA strains isolated at various times were identical by PFGE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659653     DOI: 10.1016/s0924-8579(03)00263-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

1.  Rapid depletion of free vancomycin in medium in the presence of beta-lactam antibiotics and growth restoration in Staphylococcus aureus strains with beta-lactam-induced vancomycin resistance.

Authors:  Chie Yanagisawa; Hideaki Hanaki; Hidehito Matsui; Shinsuke Ikeda; Taiji Nakae; Keisuke Sunakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

Review 2.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.